

CAPITOL STREET

June 8, 2026

Health Policy Peek: Week of June 8-12

CMS Meeting on 2027 Lab Pay (ADLT), Hearing on Price Transparency Bills, China Language in Senate Approps Package?

ICYMI

USTR Proposes Sec. 301 Tariffs on 60 Nations w/ Sec. 232 MedTech Report Still Pending ([here](#)): The U.S. Trade Representative (USTR) on June 2 proposed Sec. 301 tariffs of 10% to 12.5% on imports from 60 trading partners due to forced labor practices in supply chains. Public comments will be accepted through July 6, followed by a hearing on July 7 ([here](#)). Meanwhile, a Sec. 232 MedTech report was due to the President by June 1 (our take [here](#)) and we may hear nothing for several weeks/months.

OUR TAKE: On MedTech, we understand the Administration is looking at the impact of MedTech potential 232 tariff on affordability, given the concerns over premiums, out of pocket and healthcare overall. Tariffs under Sec. 301 and Sec. 232 both require formal investigations and are intended to partially offset IEEPA tariffs struck down by SCOTUS in February. Sec. 301 tariffs usually have a duration limit of four years and there is no percentage cap.

WEEK AHEAD

GOP Nears Final Passage of Recon 2.0 (Minus Controversial Policies & Healthcare): Following Senate passage early Friday morning, House Republicans are expected to put the finishing touches on the GOP's second reconciliation bill funding the Department of Homeland Security, U.S. Immigration and Customs Enforcement, and U.S. Customs and Border Protection. Republicans are then expected to attempt a third reconciliation bill focused on affordability and fraud prevention for the end of July as healthcare is not addressed in Recon 2.0 ([here](#)).

OUR TAKE: We think that 2.0 will pass but do not feel a Recon 3.0 will be successful at this time. On healthcare, a bipartisan package of healthcare extenders (community health centers, rural hospital provisions) and other policies is likely to emerge in a lame duck package closer to year end. Codification of MFN is unlikely to be included despite support from the White House.

Senate Appropriations FY27 FDA Funding Bill ~ Does China Language Stand?: The Senate is expected to consider FY 2027 funding bills for Commerce-Justice-Science, Legislative Branch, Agriculture-FDA, Military Construction-VA, and Interior-Environment, while House Republicans are advancing their own FY 2027 spending bills largely along party-line votes. Date TBD.

OUR TAKE: The House provision is non-binding, but the growing congressional and administration focus on China could result in some restriction during next year's PDUFA reauthorization. Still, if it does appear and pass, FDA will have to promulgate rules for it to take effect, which will depend entirely on the next FDA Commissioner.

Chinese biotechs also face other legislative risks, including proposed limits on financing, M&A, and research partnerships (COINS, BINSAs) (our take [here](#)).

ANY DAY NOW

CVS & UNH FTC Agreement/Settlement: A proposed [settlement](#) with CVS Caremark was reached in March, with formal details TBA imminently. We could see a potential settlement with [Optum](#) soon as well per recent reports. The FTC final 6B report may be delayed to post-CVS and -UNH announcements, or Spring/Summer 2026. We also note that on May 11, UNH's Optum Rx announced plans to decouple PBM profits from manufacturers' list prices ([here](#)).

OUR TAKE: We expect CVS and UNH settlements to mirror the CI agreement from [February](#), including transparency requirements, access to TrumpRx, focus on net pricing, and domestic onshoring of GPOs (for UNH), with compliance by Jan 1, 2028. We note that provisions included in the settlement reflect the Administration's priorities. We expect the FTC to continue to use these settlements to advance broader policy priorities as Trump looks to highlight wins with the upcoming mid-terms.

MON, JUNE 8

CMS Final NCD on Biomarker Tests for Colorectal Cancer Screening: CMS will likely finalize its March [proposal](#) to cover Genescopy's biomarker test for colorectal cancer screening.

TUES, JUNE 9

House Approps Markup of FY27 Labor-HHS Bill ~ NIH Flat ([here](#)): The House Appropriations Committee (Chair Cole, R-OK) will hold an 11 a.m. markup of the FY 2027 Labor-HHS Appropriations bill.

OUR TAKE: The Labor-HHS Subcommittee cleared the [bill](#) on Friday with flat funding for NIH at \$48.8 B for FY 2027. There is bipartisan and bicameral support for NIH despite President Trump's FY 2027 budget proposing a \$5 B (-11%) cut. The bill also prioritizes biodefense and the competitive risk from China, which we believe will be a recurring theme through mid-2027 (our take [here](#)).

WED, JUNE 10

CMS Meeting on CY27 Lab Pay ([here](#)): CMS will hold its CY 2027 Clinical Laboratory Fee Schedule (CLFS) annual public meeting, allowing public input on establishing payment amounts for new or substantially revised HCPCS codes. Companies on the agenda include ABT, BDSX, CSTL, HOLX, LH, NTRA, TMO, VCYT, VITR, VRCI, and ZBH.

OUR TAKE: CMS meetings this Summer (June 10 & July 14-15) and Fall will be key indicators for the future of Advanced Diagnostic Laboratory Tests (ADLTs), though we don't foresee any near-term structural changes. The PAMA data reporting period for Clinical Diagnostic Laboratory Tests (CDLTs) is May 1 to July 31, followed by data analysis and proposed & finalized pay determinations in the Fall and new rates effective Jan. 1, 2027 (timeline [here](#)). Stakeholders are hopeful PAMA reform (*RESULTS ACT*) will get added to a year-end bill, but bill score (cost) remains an issue (our take [here](#)).

House Hearing on Price Transparency Bills ([here](#)): The House Energy & Commerce Health Subcommittee (Chair Griffith, R-VA) will hold a 10:15 a.m. hearing on “Lowering Health Care Costs for All Americans: Examining Policies to Increase Health Care Transparency.” The committee will discuss nine bills on price transparency in healthcare.

OUR TAKE: Among the bills to be discussed includes a discussion draft of the *Lower Costs, More Transparency Act*, which passed the House in 2023, but stalled in the Senate (our prior take [here](#)). Unlike the 2023 version, the discussion draft doesn’t appear to include any site-neutral payment policies. We could see more transparency reforms move this year, as the bills focus on hospital price posting, insurer overhead and claim denial disclosures, and Medicare Advantage encounter data, expanding the transparency push beyond hospitals.

ON THE HORIZON

- CMS IRA drug negotiation proposed rule for 2029 (**imminent**)
- CVS & UNH FTC Agreements/Settlements (**mid-2026**)
- FTC PBM 6B study final report (**may not be released for some time due to pending FTC settlements with CVS & UNH**)
- DOL final rule on PBM (**late Spring/Summer 2026**)
- CMS announces DME CBP timeline and launches bidder education (**Summer 2026**)
- CDC ACIP meeting (**June 24-26, 2026**)
- CMS proposed CY27 Outpatient Hospital/ASC, PFS, Home Health, & ESRD rules (**Early July 2026**)
- CMS launch of Medicare GLP-1 Bridge in Medicare (**July 1, 2026**)
- USMCA joint review (**July 1, 2026**)
- USTR hearing on proposed Sec. 301 tariffs (**July 7, 2026**)
- CMS Advisory Panel on Clinical Diagnostic Laboratory Tests (**July 14-15, 2026**)
- CMS final FY27 Inpatient Hospital/LTCH, Psych, IRF, SNF, & Hospice rules (**August 2026**)
- CMS DME CBP bidder registration and bid submission open (**Summer/Fall 2026**)
- CMS Advisory Panel on Clinical Diagnostic Laboratory Tests (**September 15-16, 2026**)
- Start of FY 2027 (**Oct. 1, 2026**)
- CMS launch of GLOBE model in Medicare Part B (**Oct. 1, 2026**)
- CDC ACIP meeting (**Oct. 21-23, 2026**)
- CMS final CY27 Outpatient Hospital/ASC, PFS, Home Health, & ESRD rules (**Early-Nov, 2026**)
- Deadline for CMS to publish 2028 negotiated maximum fair prices (**Nov. 30, 2026**)
- Mid-term elections (**Nov. 3, 2026**)
- CMS CY2027 Clinical Lab Fee Schedule (**Late-December 2026**)
- CMS launch of GUARD model in Medicare Part D (**Jan. 1, 2027**)
- CMS MFP Effective for 2027 Selected Drugs (**Jan. 1, 2027**)
- CMS DME CBP contracts awarded and payment rates announced (**Summer/Fall 2027**)
- FDA PDUFA and MDUFA reauthorization deadline (**Oct. 1, 2027**)
- CMS DME CBP new contracts and rates take effect (**Jan. 1, 2028**)

CMS Coverage Decisions

- CMS Draft NCD on TAVR for Asymptomatic Patients (EW) (**June 15, 2026**)
- CMS Final NCD on TAVR for Asymptomatic Patients (EW) (**Sept. 13, 2026**)

Ipsita Smolinski
Managing Director | Capitol Street
ipsita@capitol-street.com

202.250.3741 | www.capitol-street.com

900 19th St NW 6th Fl
Washington, D.C. 20006

CAPITOL STREET

Copyright 2026 Capitol Street.

This communication, including this broadcast and any attachments hereto, is intended solely for the original recipient(s) and may not be redistributed without the written consent of Capitol Street. This communication is for informational purposes only and is not

intended as an offer or solicitation for the purchase or sale of any financial instruments, nor is it intended as advice to purchase or sell such instruments